ECSP013952A - Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina - Google Patents

Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina

Info

Publication number
ECSP013952A
ECSP013952A EC2001003952A ECSP013952A ECSP013952A EC SP013952 A ECSP013952 A EC SP013952A EC 2001003952 A EC2001003952 A EC 2001003952A EC SP013952 A ECSP013952 A EC SP013952A EC SP013952 A ECSP013952 A EC SP013952A
Authority
EC
Ecuador
Prior art keywords
oral administration
ciprofloxacine
administration system
daily intake
controlled oral
Prior art date
Application number
EC2001003952A
Other languages
English (en)
Inventor
Naresh Talwar
John N Staniforth
Ashok Rampal
Gour Mukherji
N Bradi Vishwanathan
Brij Khera
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of ECSP013952A publication Critical patent/ECSP013952A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es una fórmula contenida en una tableta diaria para administración oral a humanos para la liberación controlada de Ciprofloxacina, que comprende una cantidad de ciprofloxacina farmacéuticamente efectiva, desde alrededor de 0.1% hasta alrededor de 8.0% de una gente viscolizante y/o un agente de gelación, alrededor de 5.0% hasta alrededor de 15% de un agente generador de gas (efervescencia) y alrededor de 3.0% hasta alrededor de 15% de un agente de expansión, estando dichos porcentajes en relación de peso/peso del compuesto.
EC2001003952A 2000-03-03 2001-03-01 Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina ECSP013952A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51788700A 2000-03-03 2000-03-03

Publications (1)

Publication Number Publication Date
ECSP013952A true ECSP013952A (es) 2002-04-23

Family

ID=24061635

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001003952A ECSP013952A (es) 2000-03-03 2001-03-01 Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina

Country Status (31)

Country Link
EP (1) EP1263409A1 (es)
JP (1) JP2003525229A (es)
KR (1) KR20030009374A (es)
CN (1) CN1420763A (es)
AP (2) AP1485A (es)
AR (1) AR032614A1 (es)
AU (1) AU3589701A (es)
BG (1) BG107055A (es)
BR (1) BR0108958A (es)
CA (1) CA2400950A1 (es)
CZ (1) CZ20022883A3 (es)
DO (1) DOP2001000130A (es)
EA (1) EA200200914A1 (es)
EC (1) ECSP013952A (es)
EE (1) EE200200497A (es)
GT (1) GT200100033A (es)
HN (1) HN2001000038A (es)
HR (1) HRP20020715A2 (es)
HU (1) HUP0204417A3 (es)
IL (1) IL151553A0 (es)
IS (1) IS6532A (es)
MX (1) MXPA02008568A (es)
NO (1) NO20024108L (es)
NZ (1) NZ520927A (es)
OA (1) OA12381A (es)
PE (1) PE20011113A1 (es)
PL (1) PL365071A1 (es)
SK (1) SK12542002A3 (es)
WO (1) WO2001064183A1 (es)
YU (1) YU66202A (es)
ZA (1) ZA200206764B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10351448A1 (de) 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE602005007205D1 (de) * 2005-07-19 2008-07-10 Ethypharm Sa Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
EP1880722B1 (en) * 2006-07-19 2010-03-17 Tabuk Pharmaceutical Manufacturing Co. Pharmaceutical compositions of ciprofloxacin
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
WO2017143438A1 (en) * 2016-02-23 2017-08-31 Matripharm International Inc. Dual-rate release formulation with high drug loading
AU2017236977B2 (en) 2016-03-24 2022-05-26 Immunomolecular Therapeutics, Inc. Methods of treating autoimmune disease
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN109806237A (zh) * 2019-03-13 2019-05-28 悦康药业集团上海制药有限公司 一种乳酸环丙沙星泡腾片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE19839057A1 (de) * 1998-08-28 2000-03-02 Koch Berthold Spülluft-Regler für eine Trockenvorrichtung für Druckluft
EE200100153A (et) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Kontrollitav ravimiväljutussüsteem ravimite suukaudseks manustamiseks, mis pakub ajalist ja ruumilist kontrolli

Also Published As

Publication number Publication date
EP1263409A1 (en) 2002-12-11
PL365071A1 (en) 2004-12-27
YU66202A (sh) 2005-09-19
KR20030009374A (ko) 2003-01-29
NO20024108L (no) 2002-10-25
ZA200206764B (en) 2003-03-04
BR0108958A (pt) 2003-09-30
GT200100033A (es) 2001-10-25
HUP0204417A2 (en) 2003-05-28
CA2400950A1 (en) 2001-09-07
JP2003525229A (ja) 2003-08-26
HUP0204417A3 (en) 2005-03-29
CZ20022883A3 (cs) 2003-04-16
CN1420763A (zh) 2003-05-28
AP1485A (en) 2005-10-31
IS6532A (is) 2002-08-28
AP2002002627A0 (en) 2002-09-30
BG107055A (bg) 2003-06-30
AP2001002084A0 (en) 2001-03-31
MXPA02008568A (es) 2003-02-24
HN2001000038A (es) 2005-03-23
IL151553A0 (en) 2003-04-10
OA12381A (en) 2004-09-06
AR032614A1 (es) 2003-11-19
PE20011113A1 (es) 2001-10-14
NO20024108D0 (no) 2002-08-28
SK12542002A3 (sk) 2003-05-02
HRP20020715A2 (en) 2004-12-31
DOP2001000130A (es) 2004-03-31
NZ520927A (en) 2003-06-30
EA200200914A1 (ru) 2003-02-27
WO2001064183A1 (en) 2001-09-07
EE200200497A (et) 2004-02-16
AU3589701A (en) 2001-09-12

Similar Documents

Publication Publication Date Title
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
PE20030602A1 (es) Composicion farmaceutica que comprende un macrolido
RS20110564A2 (en) ONE-DAY OXYCODON FORMULATIONS
ECSP013952A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
NO20055880L (no) Memantin orale doseringsformer
ATE206921T1 (de) Eletriptanhemisulfat und kaffein enthaltende pharmazeutische zusammenstellungen
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
CO5280073A1 (es) Composiciones
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DE60115402D1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
MY137516A (en) Pharmaceutical composition comprising lumiracoxib
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
MY129314A (en) Pharmaceutical composition comprising sumatriptan
BR0307320A (pt) Sistema de liberação osmótico
UY26605A1 (es) Sistema de administración oral controlada para la ingestión diaria de ciprofloxacina
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
SV2003000335A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas